Shares in Mylan (NSDQ:MYL) rose 2% in pre-market activity today after the EpiPen maker beat earnings expectations on Wall Street with its 1st quarter results.
The Canonsburg, Penn.-based company posted profits of $66.4 million, or 12¢ per share, on sales of $2.72 billion for the 3 months ended March 31, for bottom-line growth of 377.7% on sales growth of 24.2% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan beats Q1 earnings by a penny, misses on revenue appeared first on MassDevice.